You are here

Recent Pfizer Press Releases

8/24/16 2:00am EDT
Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca

  • Strong fit with Pfizer’s existing anti-infective portfolio
  • Pfizer’s focus on infectious disease and expertise in this category will help enable broader access to anti-infective portfolio
  • Expected to enhance near-term revenue growth potential for Pfizer’s Essential Health business

Pfizer Inc. (NYSE:PFE) today announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infectives business, primarily outside the United States.

more...
8/23/16 6:59am EDT
Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016

Nineteen abstracts to be presented, including new post-hoc sub-analyses from the ARISTOTLE Phase 3 trial and multiple retrospective real-world data analyses from ACROPOLIS

8/22/16 6:45am EDT
Pfizer To Acquire Medivation

  • Propels Pfizer into a leading position in oncology
  • Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion
  • Expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first full year after close with additional accretion and growth anticipated thereafter

Pfizer Inc. (NYSE:PFE) and Medivation, Inc. (NASDAQ:MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. 

 

more...
8/19/16 6:21pm EDT
FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

more...
8/8/16 8:00am EDT
Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5.5 years, showed that treatment with VYNDAQEL initiated during the early stage of the disease resulted in minimal neurological disease progression and in preservation of body weight, which often declines as the disease progresses. VYNDAQEL was well tolerated with no new safety signals observed.

more...
8/2/16 6:45am EDT
PFIZER REPORTS SECOND-QUARTER 2016 RESULTS

Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink: http://www.pfizer.com/system/files/presentation/Q2_2016_PFE_Earnings_Press_Release_lkasdvfjlskad.pdf

more...
8/1/16 10:00am EDT
PFIZER AIMS TO BECOME INDUSTRY LEADER IN GENE THERAPY WITH AQUISITION OF BAMBOO THERAPEUTICS, INC.

Acquisition combines Bamboo’s gene therapy portfolio, advanced vector design, and production technologies and capabilities with Pfizer’s global scale, research, development and commercialization experience

 

Pfizer Inc. (NYSE:PFE) today announced that it has acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C., focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system.

more...
7/28/16 4:10pm EDT
Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ® (Tofacitinib Citrate) in Ulcerative Colitis

Pfizer Inc. (NYSE:PFE) announced today top-line results from Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) Sustain, the third Phase 3 study of XELJANZ® (tofacitinib citrate) being investigated in patients with moderately to severely active ulcerative colitis (UC).

more...
7/28/16 10:00am EDT
Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology

Companies plan to advance Western Oncolytics’ lead preclinical therapy into human testing

Potential combination of WO-12 with Pfizer’s oncology pipeline could enhance therapeutic benefit in patients

Pfizer Inc. (NYSE:PFE) and Western Oncolytics announced today that they have entered into a development collaboration, license and option agreement to advance Western Oncolytics’ novel oncolytic vaccinia virus, WO-12. Oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer immune responses. This collaboration in oncolytic virus development adds another novel technology platform to Pfizer’s cancer vaccine efforts and provides an additional tool to bolster its immuno-oncology portfolio.

more...
7/21/16 12:01pm EDT
Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B

PHILADELPHIA and NEW YORK CITY, July 21, 2016 -- Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced today that the U.S.

more...
7/19/16 8:00am EDT
Pfizer Receives World Health Organization Prequalification for Multi-Dose Vial Presentation of Prevenar 13®

Designation Will Enable Increased Access to Vaccine in World’s Poorest Countries

Pfizer Inc. (NYSE: PFE) announced today that the World Health Organization (WHO) has prequalified its four-dose, multi-dose vial (MDV) presentation of Prevenar 13®* (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). WHO prequalification allows for the global use of Prevenar 13® MDV by United Nations agencies and countries worldwide that require WHO prequalification.

more...
7/13/16 8:00am EDT
Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis

Phase 3 Data Published in the Journal of the American Academy of Dermatology

Pfizer Inc. (NYSE:PFE) announced today the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% (formerly AN2728) in the online issue of the Journal of the American Academy of Dermatology.

more...
7/12/16 4:04pm EDT
Pfizer Receives FDA Approval for Prevnar 13® in Adults Age 18 Through 49

Prevnar 13 is the only pneumococcal vaccine approved in the U.S. for patients 6 weeks through adulthood

Pfizer Inc. (NYSE:PFE) today announced that Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.S. Food and Drug Administration (FDA) approval for an expanded age indication to include adults 18 through 49 years of age, in addition to the already approved indication for adults 50 years and older, for active immunization for the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae (S. pneumoniae) serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).

more...
7/8/16 8:00am EDT
Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT® (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma

S-TRAC is the First RCC Trial of a Tyrosine Kinase Inhibitor to Prolong Disease-Free Survival in the Adjuvant Setting

Pfizer Inc. (NYSE:PFE) today announced that the S-TRAC clinical trial (Sunitinib Trial in Adjuvant Renal Cancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of improving disease-free survival (DFS) as determined by blinded independent central review in patients with renal cell carcinoma (RCC) who are at high risk for recurrence after surgery.

more...
7/6/16 8:00am EDT
Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer

First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer

New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of avelumab* in combination with, and/or as follow-on (maintenance) treatment to, platinum-based chemotherapy in patients with locally advanced or metastatic disease (Stage III or Stage IV) with previously untreated epithelial ovarian cancer. JAVELIN Ovarian 100 is the first Phase III study evaluating the addition of an immune checkpoint inhibitor to standard-of-care in first-line treatment for this aggressive disease.

more...
6/28/16 8:30am EDT
Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results

SPIRE-HR and SPIRE-FH trials met primary endpoints in patients at high and very high risk for cardiovascular events

Pfizer Inc.

more...
6/27/16 11:30pm EDT
Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China

Pfizer’s state-of-the-art facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reforms

Pfizer Inc. today announced that it will invest approximately USD$350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in China.

more...
6/24/16 9:00am EDT
Pfizer Completes Acquisition of Anacor

Tender offer for all of the outstanding shares of Anacor common stock expired as scheduled immediately after 11:59 p.m., New York City time, on June 23, 2016

Pfizer and Anacor begin joint operations on June 24, 2016

Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive $99.25 net in cash (without interest but subject to required withholding of taxes).

more...
6/23/16 4:00pm EDT
Pfizer Declares 30-Cent Third-Quarter 2016 Dividend

The board of directors of Pfizer Inc. today declared a 30-cent third-quarter 2016 dividend on the company’s common stock, payable September 1, 2016, to shareholders of record at the close of business on August 5, 2016. The third-quarter 2016 cash dividend will be the 311th consecutive quarterly dividend paid by Pfizer.

Pfizer Inc.

more...
6/21/16 10:00am EDT
Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 2, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2016 Performance Report, to be issued that morning.

more...

Pages